Anthony M. Magliocco
H. Lee Moffitt Cancer Center and Research Institute
United States of America
Dr. Anthony Magliocco is a Senior Member and Chair, Department of Anatomic Pathology at Moffitt Cancer Center as well as Executive Director of Esoteric Laboratory Services and the Morsani Molecular Diagnostic Laboratory, and Scientific Director of the Moffitt Tissue Core. He is Board Certified in Anatomic Pathology. Dr. Magliocco has subspecialty expertise in breast, gynecological and molecular pathology and research interests in the areas of molecular predictive markers, digital analytical microscopy, and personalized medicine. Dr. Magliocco earned his MD at the University of Alberta, Edmonton, Canada. He completed an Anatomical Pathology Residency at the University of Calgary in the Department of Pathology at Foothills Hospital and Fellowships in Anatomical Pathology at Royal College of Physicians and Surgeons of Canada and College of American Pathologists FCAP Fellow. He completed a Post-Doctoral Fellowship in Molecular Surgical Pathology at Fox Chase Cancer Center. In 2011 Dr. Magliocco was recruited to Moffitt Cancer Center to lead the Anatomic Pathology Department and lead the esoteric laboratory services program. He has worked to establish the Moffitt Morsani Molecular Laboratories and a new CLIA microscopic digital image analysis facility. These new laboratory programs bring innovative CLIA grade testing services to Moffitt patients and physicians supporting the Personalized Medicine Program. Advanced testing services include next generation sequencing, circulating tumor cell analysis, cell free nucleic acid analysis and complex multiplex analytical tissue imaging. In addition Dr. Magliocco has established new fellowship programs in molecular diagnostics and digital image analysis. He Co-Chairs the NRG Oncology pathology committee and is a member of the NCI GU cancer steering committee. He also established the Annual Moffitt Pathology Symposium in 2013 and serves as its course director. Dr. Magliocco’s clinical interest is in the development of novel molecular testing for integration into routine clinical service. His research focuses on understanding the molecular basis of cancer progression including the mechanisms of metastasis and development of resistance to therapeutics including the basis of radiotherapy resistance with a major focus on women’s cancers.
He is interested in the development of clinical markers of radiotherapy resistance using cervical cancer as a model system. His clinical interests focus on molecular biomarker development for improving cancer treatment. In addition he has special expertise in breast and gynecological pathology. Finally, Dr. Magliocco has interests in developing approaches for improving the quality of cancer pathology laboratories.
Petersen LF, Klimowicz AC, Otsuka S, Elegbede AA, Petrillo SK, et al. (2017) Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC. Oncotarget 8:38326-38336.
Chen Y, Britton D, Wood ER, Brantley S, Magliocco A, et al.(2017) Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers. Proteomics p: 17.
Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, et al. (2017) Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep Sep 7:10484.